Geron Corporation
$ 1.61
-0.62%
11 Feb - close price
- Market Cap 1,034,136,000 USD
- Current Price $ 1.61
- High / Low $ 1.69 / 1.56
- Stock P/E N/A
- Book Value 0.39
- EPS -0.12
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.30 %
- 52 Week High 2.84
- 52 Week Low 1.04
About
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.03 | -0.02 | -0.03 | -0.0356 | -0.04 | -0.1 | -0.09 | -0.09 | -0.08 | -0.09 | -0.07 | -0.1 |
| Estimated EPS | -0.0256 | -0.03 | -0.0357 | -0.0464 | -0.08 | -0.1 | -0.1 | -0.1 | -0.1 | -0.08 | -0.1 | -0.12 |
| Surprise | -0.0044 | 0.01 | 0.0057 | 0.0108 | 0.04 | 0 | 0.01 | 0.01 | 0.02 | -0.01 | 0.03 | 0.02 |
| Surprise Percentage | -17.1875% | 33.3333% | 15.9664% | 23.2759% | 50% | 0% | 10% | 10% | 20% | -12.5% | 30% | 16.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GERN
2026-02-11 12:43:00
Geron Corporation announced it will release its fourth quarter and full year 2025 financial results and business highlights on Wednesday, February 25, 2026, before market open. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® approved for certain adult patients with LR-MDS.
2026-02-10 08:58:51
Geron Corporation (NASDAQ:GERN) shares have recently crossed above their 200-day moving average, trading as high as $1.6275 with a significant volume of 15.38 million shares. The stock has a consensus "Hold" rating from analysts with an average price target of $2.75, following mixed reports, including some reiterating "buy" and "neutral" ratings, and one lowering a price target. Institutional investors have also shown increased activity, with several firms adjusting their positions in the biopharmaceutical company.
2026-02-06 20:59:54
Geron Corporation's stock (NASDAQ: GERN) is up 4.79% following promising developments, including FDA designations. The company projects significant RYTELO product revenues of $220M-$240M for fiscal year 2026 and is expanding its commercial ventures internationally. Despite an analyst lowering the price target to $3 from $4, maintaining a 'Buy' rating, the company faces profitability challenges but retains a positive long-term outlook.
2026-02-03 09:58:49
Geron Corporation (NASDAQ:GERN) currently has a low price-to-sales (P/S) ratio of 5.4x compared to the biotech industry average, suggesting a bearish outlook from the market. While the company has shown strong historical revenue growth, analysts project a significantly lower annual revenue growth of 39% over the next three years, compared to the industry's 139%. This anticipated underperformance in growth is likely contributing to its subdued P/S ratio, indicating that investors are not currently willing to pay a premium for the stock.
2026-02-02 17:28:06
Geron Corporation's stock has risen by 9.85% following positive FDA designations and promising results for its drug RYTELO. TD Cowen analyst Tara Bancroft adjusted Geron’s price target from $4 to $3 but maintained a Buy rating, as Geron anticipates RYTELO's 2026 revenue to be between $220M and $240M and plans global expansion and further clinical trials. The company is actively focusing on balancing revenue growth with managing operating expenses.
2026-02-02 16:28:06
Geron Corporation's stock (NASDAQ: GERN) recently saw a 9.38% increase due to promising clinical trial results for its key product, RYTELO, and positive revenue forecasts for 2026. Despite a current net income loss of $18.43 million, the company's strategic investments in U.S. market expansion and the Phase 3 IMpactMF trial indicate a growth-driven strategy. Analysts maintain a "Buy" rating, signaling confidence in Geron's long-term potential as it navigates financial challenges and pursues product expansion.
